Eosinophil Viability-Enhancing Activity in Mite-Sensitive Bronchial Asthma
1994 Volume 33 Issue 9 Pages 529-535
Details
1994 Volume 33 Issue 9 Pages 529-535
We examined the eosinophil viability-enhancing activity (EVEA) of peripheral blood mononuclear cells (PBMNCs) obtained from 6 patients with mite-sensitive bronchial asthma (BA) and 9 normal control subjects. Mite concentrations of 1μg/ml and 10 μg/ml significantly increased EVEA in PBMNC culture supernatants from BA patients compared with PBMNCs from normal control subjects (76.1±11.0% at 10 μg/ml and 56.3±16.0% at 1 μg/ml vs 20.6±012.6% at 10 μg/ml and 7.4±2.3% at 1 μg/ml; p<0.05). The level of IFN-γ in PBMNC culture supernatants in BA patients was 2.3±0.9 IU/ml and in normal control subjects 0.7±0.3 lU/ml. A combination of mAbs (anti-IL3, anti-IL-5 and anti-GM-CSF, with or without anti-IFN-γ) neutralized the EVEA (p<0.001, p<0.001, respectively). Dexamethasone (10-8 M to 10-5 M), cyclosporin A (10-7 M to 10-5 M) and FK506 (10-8 M to 10-6 M) significantly inhibited EVEA in BA patients (p<0.05 to p<0.001). The release of eosinophil cationic protein (ECP) from eosinophils in the presence of mite-stimulated PBMNC culture supernatants was higher in patients with bronchial asthma (569±147 μg/l) than in normal control subjects (203±99 μg/1; p<0.05).
(Internal Medicine 33: 529-535, 1994)
